Corrigendum: Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents (Journal of Thrombosis and Haemostasis (2014) 12(11) (1810–1815), (S1538783622040995), (10.1111/jth.12720));Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 11, 2014, Pages 1810-1815

  Dale, B J ^a   Ginsberg, J S ^b,c   Johnston, M ^d   Hirsh, J ^b   Weitz, J I ^b,c   Eikelboom, J W ^b,c,e  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d Hemostasis Reference Laboratory   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

Activated partial thromboplastin time; Anticoagulants; Apixaban; Prothrombin time; Rivaroxaban

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN; THIOPHENE DERIVATIVE;

BLOOD CLOTTING; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; HUMAN; PARTIAL THROMBOPLASTIN TIME; PREDICTIVE VALUE; PROCEDURES; PROTHROMBIN TIME; REPRODUCIBILITY;

BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA INHIBITORS; HUMANS; MORPHOLINES; PARTIAL THROMBOPLASTIN TIME; PREDICTIVE VALUE OF TESTS; PROTHROMBIN TIME; PYRAZOLES; PYRIDONES; REPRODUCIBILITY OF RESULTS; THIOPHENES;

EID: 84920262449     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12840     Document Type: Erratum

References (16)

1. Asmis LM, Alberio L, Angelillo-Scherrer A, Korte W, Reber G, Seifert B, Stricker H, Tsakiris DA, Wuillemin WA. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests. A study in 9 Swiss laboratories. Thromb Res 2012; 129: 492-8.
2. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263-71.
3. Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, Alexander JH. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 2011; 32: 183-7.
4. Food and Drug Administration. Clinical pharmacology and biopharmaceutics review. http://www.accessdata.fda.gov/drugsatfda_docs/2012/202155Orig1s000ClinPharmR.pdf. Accessed 30 August 2013.
5. Mueck W, Lensing AWA, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Population pharmacokinetic analyses in patients treated for acute deep vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 50: 675-86.
6. Douxfils J, Chatelain C, Chatelain B, Dogne J-M, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013; 110: 283-94.
7. Hillarp A, Gustafsson KM, Faxalv L, Strandberg K, Baghaei F, Fagerberg Blixter I, Berndtsson M, Lindahl TL. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-Xa assays. J Thromb Haemost 2014; 12: 1545-53.
8. Douxfils J, Mullier F, Loosen C, Chatelain C. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012; 130: 956-66.
9. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, Strabdberg K, Lindhal TL. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2010; 9: 133-9.
10. Samama MM, Martinoli J-L, leFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzbon E. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-25.
11. Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou M-H, Laporte S. Assessment of apixaban levels by laboratory tests: suitability of three anti-Xa assays. Thromb Haemost 2014; 111: 1-9.
12. Samama MM, Contant G, Spiro TE, Perzborn E, Le Flem L, Guinet C, Gourmelin Y, Martinoli JL. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentration using calibrators and controls: results of a multicentre field trial. Clin Appl Thromb Hemost 2012; 18: 150-8.
13. Douxfils J, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Mullier F, Dogne J-M. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013; 110: 723-31.
14. 14C-labeled apixaban in mice, rats, rabbits, dogs and humans. Drug Metab Dispos 2009; 37: 1738-48.
15. Wang L, Raghavan N, He K, Luettgen JM, Humphreys WG, Knabb RM, Pinto DJ, Zhang D. Sulfation of O-demethyl apixaban: enzyme identification and species comparison. Drug Metab Dispos 2009; 37: 802-8.
16. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009; 37: 1056-64.